| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Advisory Board and Contents
|
|
|
|
43 |
8 |
p. i-ii
|
artikel
|
| 2 |
Atogepant (Qulipta®) for migraine prevention
|
Hay, Debbie L.
|
|
|
43 |
8 |
p. 701-702
|
artikel
|
| 3 |
Compstatins: the dawn of clinical C3-targeted complement inhibition
|
Lamers, Christina
|
|
|
43 |
8 |
p. 629-640
|
artikel
|
| 4 |
NLRP3 and pyroptosis blockers for treating inflammatory diseases
|
Coll, Rebecca C.
|
|
|
43 |
8 |
p. 653-668
|
artikel
|
| 5 |
Pharmacological targeting of the tumor–immune symbiosis in glioblastoma
|
Pang, Lizhi
|
|
|
43 |
8 |
p. 686-700
|
artikel
|
| 6 |
Present and future of microglial pharmacology
|
Šimončičová, Eva
|
|
|
43 |
8 |
p. 669-685
|
artikel
|
| 7 |
Progranulin as a therapeutic target in neurodegenerative diseases
|
Rhinn, Herve
|
|
|
43 |
8 |
p. 641-652
|
artikel
|
| 8 |
Promising neuroimmune targets and drugs for CNS diseases
|
Madukwe, Jerry
|
|
|
43 |
8 |
p. 609-610
|
artikel
|
| 9 |
Subscription and Copyright Information
|
|
|
|
43 |
8 |
p. e1
|
artikel
|
| 10 |
Targeting complement in neurodegeneration: challenges, risks, and strategies
|
Zelek, Wioleta M.
|
|
|
43 |
8 |
p. 615-628
|
artikel
|
| 11 |
The future of neuroimmunology research for CNS disease therapeutics
|
Lambris, John D.
|
|
|
43 |
8 |
p. 611-614
|
artikel
|
Tijdschrift beschrijving